The PMPRB has extended the deadline for comments on the revised draft Guidelines to August 4, 2020.
See here for further details on the change. Please also see our June 23, 2020 article for a summary of notable changes in the revised draft Guidelines.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada takes action to address generic drug submission review backlog
Health Canada is not currently meeting its performance standards for the review of some generic drug submissions. On September 1, 2026, Health Canada launched a new webpage, Improving how we review ge...Read More -
PMPRB releases September 2026 NEWSletter
The September NEWSletter also provides information about the PMPRB’s participation in past and future events, as well as NPDUIS research initiative and activities.Read More -
Health Canada provides its quarterly update and PMPRB publishes the 10th edition of the Meds Entry Watch report
On October 15, 2026, Health Canada provided its quarterly update summarizing steps it has taken “to make its regulatory processes more modern and efficient, while maintaining high standards for safety...Read More
